Literature DB >> 8902889

Preferential transmission of the high activity allele of COMT in schizophrenia.

T Li1, P C Sham, H Vallada, T Xie, X Tang, R M Murray, X Liu, D A Collier.   

Abstract

Catechol-O-methyl transferase (COMT) metabolizes a variety of catecholamines such as dopamine, adrenaline and noradrenaline. It exists in common high and low activity forms. The low activity form is the result of an amino acid substitution (val-108-met) which reduces the thermostability of the enzyme [Lotta et al. (1994) Biochemistry, 34, 4202-4210]. We have genotyped this polymorphism in 178 trios consisting of Han Chinese schizophrenic subjects and their parents in order to test the hypothesis that the high activity allele is transmitted more often to affected subjects. The data were analysed using the transmission disequilibrium test (TDT), a robust method of detecting linkage in the presence of allelic associations. Of the 131 parents heterozygous at this locus, 80 transmitted the high activity allele (val-108) to affected offspring, while the remaining 51 transmitted the low activity allele (p = 0.005, one-tailed). Combining this result with that of a previous TDT study of the same polymorphism in familial schizophrenia [Kunugi et al. (1996) submitted] gives significant evidence for linkage disequilibrium (p = 0.0015). However, val-108 is frequent in the Han Chinese population, and in the present sample, 239 of the 350 non-transmitted parental alleles were val-108 (68%). It is therefore unlikely that val-108 allele of COMT has a major effect on susceptibility to schizophrenia. Our results suggest that either val-108 is a minor risk factor for schizophrenia, that the COMT gene has additional polymorphisms with greater effect on risk, or that this region of chromosome 22 contains a susceptibility gene which is in linkage disequilibrium with the COMT gene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8902889     DOI: 10.1097/00041444-199623000-00005

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  29 in total

Review 1.  Linkage and association studies of schizophrenia.

Authors:  Peter McGuffin; Kopal Tandon; Alejandro Corsico
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

2.  Nucleocytoplasmic shuttling of dysbindin-1, a schizophrenia-related protein, regulates synapsin I expression.

Authors:  Erkang Fei; Xiaochuan Ma; Cuiqing Zhu; Ting Xue; Jie Yan; Yuxia Xu; Jiangning Zhou; Guanghui Wang
Journal:  J Biol Chem       Date:  2010-10-04       Impact factor: 5.157

Review 3.  Genetic abnormalities of chromosome 22 and the development of psychosis.

Authors:  Nigel M Williams; Michael J Owen
Journal:  Curr Psychiatry Rep       Date:  2004-06       Impact factor: 5.285

Review 4.  Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes.

Authors:  William R Perlman; Cynthia Shannon Weickert; Mayada Akil; Joel E Kleinman
Journal:  J Psychiatry Neurosci       Date:  2004-07       Impact factor: 6.186

5.  Biological phenotypes and genetic research on schizophrenia.

Authors:  Daniel R Weinberger
Journal:  World Psychiatry       Date:  2002-02       Impact factor: 49.548

6.  Development and validation of the high-quality 'rapid method for swab' to genotype the HTTLPR serotonin transporter (SLC6A4) promoter polymorphism.

Authors:  Bryan Maloney; Balmiki Ray; Elizabeth P Hayden; John I Nurnberger; Debomoy K Lahiri
Journal:  Psychiatr Genet       Date:  2009-04       Impact factor: 2.458

Review 7.  Genomic structural variation and schizophrenia.

Authors:  Jennifer Gladys Mulle
Journal:  Curr Psychiatry Rep       Date:  2008-04       Impact factor: 5.285

8.  Transmission disequilibrium, family controls, and great expectations.

Authors:  D J Schaid
Journal:  Am J Hum Genet       Date:  1998-10       Impact factor: 11.025

9.  Morphological changes in gray matter volume correlate with catechol-O-methyl transferase gene Val158Met polymorphism in first-episode treatment-naïve patients with schizophrenia.

Authors:  Ming-Li Li; Bo Xiang; Yin-Fei Li; Xun Hu; Qiang Wang; Wan-Jun Guo; Wei Lei; Chao-Hua Huang; Lian-Sheng Zhao; Na Li; Hong-Yan Ren; Hui-Yao Wang; Xiao-Hong Ma; Wei Deng; Tao Li
Journal:  Neurosci Bull       Date:  2015-01-06       Impact factor: 5.203

Review 10.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.